engleski

Intralesional administration of human leukocyte interferon (HLI) in the therapy of glioblastoma

From the beginning of February 1987 till December 1988, we have treated 35 patients with brain glioblastoma by the direct intratumoral application of human leukocyte interferon (HLI). In all patients tumor was first macroscopically radically vaporized with the carbon dioxide laser ; this was followed by the direct application of HLI. Direct intralesional administration of HLI was performed using on Omay-a reservoir implanted into the cavity after tumor removal. HLI was administered twice a week in the dose of 1.000.000 IU troughout the period of 8 weeks. The interferon therapy was combined with the therapeutic modalities and the best neurological outcome as well as survival time was found in the group of patients that were treated with radiotherapy, chemotherapy and intracavitally applied interferon. Monthly CT scans and the neurological status follow up helped in the evaluation of the therapeutic modality.

Human leucocyte interferon ; glioblastoma ; intralesional administration

nije evidentirano